Page 45 - 66_01
P. 45
VOL. 66, (1) 2000 INHIBIDORES FOSFODIESTERASA Y ASMA
(37) JACOBITZ S, McLAUGHLIN M.M, LIVI G.P, et al.. Mapping the
functional domains of human recombinant phosphodiesterase 4A:
structural requeriments for catalytic activity and rolipram binding. Mol
Pharmacol., (1996); 50: 891-899.
(38) ROCQUE W.J, HOLMES W.D, PATEL I.R, et al.. Detailed
characterization of a purified type-4 phosphodiesterase, HSPDE4B2B:
differentiation of high-affinity and low-affinity (R)-rolipram binding.
Protein Express. Purification, (1997); 9: 191-202.
(39) SOUNESS J.E, RAO S. Proposal for pharmacologically distinct
conformers of PDE4 cyclic-AMP phosphodiesterases. Cell. Signal,
(1997); 9: 227-236.
(40) DENT G, MAGNUSSEN H, RABE K.F. Cyclic nucleotide
phosphodiesterases in the human lung. Lung, (1994); 172: 129-146.
(41) SCHUDT C, GANTNER, F., TENOR H, HATZELMANN A.
Therapeutic potential of selective PDE inhibitors in asthma. Pulm.
Pharm. Ther., (1999); 12: 123-129.
23
